Mifamurtide is primarily used in the treatment of osteosarcoma, a type of bone cancer, particularly in children and young adults. It is administered as an adjunct to postoperative chemotherapy to improve survival rates. The drug works by stimulating the immune system to target and destroy cancer cells. It is typically given intravenously in a clinical setting, often in combination with other chemotherapeutic agents. Mifamurtide is especially effective in cases where the cancer has not spread widely, helping to reduce the risk of recurrence. Its use has shown significant improvement in long-term outcomes for patients undergoing treatment for non-metastatic, resectable osteosarcoma.